Related Experiment Videos
Antibodies as molecular target-based therapy: trastuzumab
1Department of Surgery, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan. tokuda@is.icc.u-tokai.ac.jp
International Journal of Clinical Oncology
|September 5, 2003
Summary
Trastuzumab, an anti-HER2 antibody, shows efficacy in treating HER2-positive breast cancer. Clinical trials demonstrate improved survival and response rates when used alone or with chemotherapy.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- HER2 gene overexpression/amplification occurs in ~30% of breast cancers, correlating with poorer survival.
- HER2 protein is a validated therapeutic target for antibody-based cancer treatments.
- Trastuzumab is a humanized monoclonal antibody targeting the HER2 protein.
Purpose of the Study:
- To review the novel biologic agent trastuzumab.
- To provide an overview of clinical studies involving trastuzumab, particularly in Japan.
Main Methods:
- Review of clinical trial data for trastuzumab in metastatic breast cancer.
- Analysis of trastuzumab's efficacy as a single agent and in combination with chemotherapy.
Main Results:
- Trastuzumab demonstrated a favorable response rate as a single agent in pre-treated metastatic breast cancer patients (Phase II trial).
- First-line treatment with trastuzumab plus chemotherapy significantly improved response rates, time to disease progression, and overall survival compared to chemotherapy alone (Phase III trial).
- Trastuzumab was generally well-tolerated in both monotherapy and combination settings.
Conclusions:
- Trastuzumab is a crucial component in the treatment strategy for HER2-positive metastatic breast cancer.
- The antibody offers significant survival benefits and is well-tolerated, establishing its role in clinical practice.